SPICLOMAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24ClN3OS2
Molecular Weight	446.028
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C2SC3=CC=CC=C3N(CCCN4CCC5(CC4)NC(=O)CS5)C2=C1

InChI

InChIKey=CFOYBMUYCBSDAL-UHFFFAOYSA-N

InChI=1S/C22H24ClN3OS2/c23-16-6-7-20-18(14-16)26(17-4-1-2-5-19(17)29-20)11-3-10-25-12-8-22(9-13-25)24-21(27)15-28-22/h1-2,4-7,14H,3,8-13,15H2,(H,24,27)

HIDE SMILES / InChI

Molecular Formula	C22H24ClN3OS2
Molecular Weight	446.028
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111088 | https://www.ncbi.nlm.nih.gov/pubmed/23840452 | https://www.ncbi.nlm.nih.gov/pubmed/16772768https://www.ncbi.nlm.nih.gov/pubmed/23840452

Spiclomazine induces apoptosis associated with the suppression of migration and invasion in pancreatic carcinoma cells

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
apoptotic process 51 Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452	Activator 1447
transformed cell apoptotic process 104 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452	Activator 1447
Adrenergic receptor 35 Target ID: CHEMBL2331074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111088	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Psychotic disorder 26 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5465392 https://www.ncbi.nlm.nih.gov/pubmed/6111088 https://www.ncbi.nlm.nih.gov/pubmed/5465391	Primary		Approved 8583	Diceplon Approved Use Antipsychotic
Pancreatic cancer 98 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Spiclomazine induces apoptosis associated with the suppression of cell viability, migration and invasion in pancreatic carcinoma cells.	2013	23840452
High performance liquid chromatography/electrospray tandem mass spectrometry for phenothiazines with heavy side chains in whole blood.	1999	10567940
Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses.	1981-02	6111088
[Studies on psychotropic drugs. V. Pharmacological effects of 8-(3-(2-chloro-10-phenothiazinyl)propyl)-1-thia-4,8-diazaspiro(4,5) decan-3-one hydrochloride (APY-606)].	1970-07	5465390

Patents

Sample Use Guides

In Vivo Use Guide

oral administration of 5-10 mg

Route of Administration: Oral

In Vitro Use Guide

Treatment with Clospirazine hydrochloride (spiclomazine) for 24 and 48 h resulted in a time and dose-dependent growth reduction of CFPAC-1 and MIA PaCa-2 cell lines examined by MTT assay. This small molecule inhibited the cell growth to approximately 61.1+/-5.3%, 76.4+/-3.2% and 90.4+/-0.5% of control in CFPAC-1 cells, and 79.3+/-1.0%, 84.5+/-1.5% and 93.6+/-0.2% of control in MIA PaCa-2 cells at the concentrations of 30, 40, and 50 mg/mL for 48 h, respectively.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:11:23 GMT 2025` Edited by `admin` on `Mon Mar 31 18:11:23 GMT 2025`
Record UNII	G2V8248111
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SPICLOMAZINE

Official Name

English

CLOSPIRAZINE [MI]

Preferred Name

English

Spiclomazine [WHO-DD]

Common Name

English

spiclomazine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710